Showing 551-575 of 1,050 results
Open
Full-Scale Hybrid Effectiveness-Implementation Trials for Mental Health Interventions (R01 - Clinical Trial Required)
National Institutes of HealthCloses in 545 days
View Details
Open
Development of Psychosocial Therapeutic and Preventive Interventions for Mental Disorders (R33 Clinical Trial Required)
National Institutes of HealthCloses in 545 days
View Details
Open
Development of Psychosocial Therapeutic and Preventive Interventions for Mental Disorders (R61/R33 Clinical Trial Required)
National Institutes of HealthCloses in 545 days
View Details
Open
Early Stage Testing of Pharmacologic or Neuromodulatory Device-based Interventions for the Treatment of Mental Disorders (R33- Clinical Trial Required)
National Institutes of HealthCloses in 545 days
View Details
Open
Early Stage Testing of Pharmacologic or Neuromodulatory Device-based Interventions for the Treatment of Mental Disorders (R61/R33 Clinical Trial Required)
National Institutes of HealthCloses in 545 days
View Details
Open
First in Human and Early Stage Clinical Trials of Novel Investigational Drugs or Neuromodulatory Device-based Interventions for Psychiatric Disorders (U01 Clinical Trial Required)
National Institutes of HealthCloses in 545 days
View Details
Open
Effectiveness Trials to Test Mental Health System Interventions (R61/R33 Clinical Trial Required)
National Institutes of HealthCloses in 545 days
View Details
Open
HIV Prevention and Alcohol (R01 Clinical Trials Optional)
National Institutes of HealthCloses in 19 days
View Details
Open
Prevention and Intervention Approaches for Fetal Alcohol Spectrum Disorders (R34 Clinical Trial Optional)
National Institutes of HealthCloses in 264 days
View Details
Open
Navigator Emergency Department Diversion Models for Non-Urgent Mental Health Concerns (R34 Clinical Trial Required)
National Institutes of HealthCloses in 629 days
View Details
Open
Prevention and Intervention Approaches for Fetal Alcohol Spectrum Disorders (R61/R33 Clinical Trial Optional)
National Institutes of HealthCloses in 213 days
View Details
Open
New Approaches for Measuring Brain Changes Across Longer Timespans (R01 Clinical Trial Optional)
National Institutes of HealthCloses in 384 days
View Details
Open
HIV Prevention and Alcohol (R34 Clinical Trials Optional)
National Institutes of HealthCloses in 19 days
View Details
Open
The Role of Work in Health Disparities in the U.S. (R01 Clinical Trials Optional)
National Institutes of HealthCloses in 629 days
View Details
Open
Navigator Emergency Department Diversion Models for Non-Urgent Mental Health Concerns (R01 Clinical Trial Required)
National Institutes of HealthCloses in 629 days
View Details
Open
New Approaches for Measuring Brain Changes Across Longer Timespans (R21 Clinical Trial Optional)
National Institutes of HealthCloses in 384 days
View Details
Open
Mood and Psychosis Symptoms during the Menopause Transition (R21 Clinical Trial Optional)
National Institutes of HealthCloses in 629 days
View Details
Open
Utilizing Invasive Recording and Stimulating Opportunities in Humans to Advance Neural Circuitry Understanding of Mental Health Disorders (R21 Clinical Trial Optional)
National Institutes of HealthCloses in 629 days
View Details
Open
Catalyze Product Definition Medical Device prototype design/testing and disease target identification and assay development (R61/R33 - Clinical Trial Not Allowed)
National Institutes of HealthCloses in 614 days
View Details
Open
Catalyze: Product Definition for Small Molecules, Biologics, and Combination Products - Preliminary Product/Lead Series Identification and Combination Product Prototype (R33 - Clinical Trial Not Allowed)
National Institutes of HealthCloses in 614 days
View Details
Open
Catalyze: Product Definition Medical Device Prototype Optimization (R33 - Clinical Trial Not Allowed)
National Institutes of HealthCloses in 614 days
View Details
Open
Occupational Safety and Health Training Project Grants (T03)
Centers for Disease Control and Prevention - ERACloses in 922 days
View Details
Open
Seamless Early-Stage Clinical Drug Development (Phase 1 to 2a) for Novel therapeutic Agents for the Spectrum of Alzheimer's Disease (AD) and AD-related Dementias (ADRD) (UG3/UH3 Clinical Trial Required)
National Institutes of HealthCloses in 215 days
View Details
Open
Utilizing Invasive Recording and Stimulating Opportunities in Humans to Advance Neural Circuitry Understanding of Mental Health Disorders (R01 Clinical Trial Optional)
National Institutes of HealthCloses in 629 days
View Details
Open
Mood and Psychosis Symptoms during the Menopause Transition (R01 Clinical Trial Optional)
National Institutes of HealthCloses in 629 days
View Details
Stay Updated
Get notified about new opportunities matching your interests.